Isomorphic Labs Secures $5 Billion to Push AI‑Designed Drugs Into Clinical Trials

1–2 minutes

Massive Series C Funding Signals Next Phase for DeepMind Spin‑out

The artificial‑intelligence drug‑discovery specialist, which emerged from Google’s DeepMind in 2021, announced a $5 billion Series C round that will fund the transition of its experimental compounds from the lab to human trials. The investment was jointly led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new backer and a host of additional investors also contributing.

Existing shareholders returned to the table, including Alphabet’s venture arms GV and Capital G, Thrive Capital, MGX, Temasek and the United Kingdom’s Sovereign AI Fund. Bloomberg reported earlier this month that the company was targeting a $50 billion valuation, though Isomorphic declined to disclose its new post‑money figure.

Isomorphic’s core offering is an AI‑driven drug‑design engine that runs a suite of simulation models to explore chemical space. The technology builds directly on DeepMind’s AlphaFold breakthrough, which predicts protein three‑dimensional structures from genetic sequences. In preclinical studies the platform has shown promise in oncology and immunology, prompting collaborations with pharmaceutical heavyweights Eli Lilly, Novartis and Johnson & Johnson.

The fresh capital follows a $2.1 billion Series B completed in May and will be allocated to further refine the design engine and broaden the therapeutic areas under investigation.

Leadership Shift and Nobel Recognition Mark a Milestone

This is the first financing since founder and chief executive Demis Hassabis stepped down from his role as head of DeepMind to devote himself full‑time to drug discovery, assuming chairman duties at the original lab. Hassabis, together with former DeepMind director John Jumper, earned the Nobel Prize in Chemistry for their work on AlphaFold, a system that can determine a protein’s shape solely from its genetic code.

The funding round underscores Isomorphic’s ambition to move from proof‑of‑concept to real‑world medicines, leveraging its AI platform to accelerate a pipeline that now spans multiple disease categories.